Stock Events

Stock Events

Telomir Pharmaceuticals 

$1.0500
60
+$0.00+0% 20:00 Today
+$0.00+0%20:02After hours

Statistics

Day High
1.13
Day Low
1.04
52W High
1.7
52W Low
0.888
Volume
34,631
Avg. Volume
100,109
Mkt Cap
77.3M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Dec 2Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.09
-0.07
-0.05
-0.03
Expected EPS
-0.03
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
2025
0Revenue
-10.41MNet Income

Analyst Ratings

$4.00Average Price Target
The highest estimate is ⁦4.00⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TELO. It's not an investment recommendation.
NVIDIA
15
NVDA
Realty Income
12
O
AGNC Investment
11
AGNC
Microsoft
10
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap158.45B
Pfizer is a major player in the pharmaceutical industry, directly competing with Telomir Pharmaceuticals in the development and marketing of drugs in similar therapeutic areas.
Merck
MRK
Mkt Cap356.01B
Merck operates in the same sectors as Telomir Pharmaceuticals, particularly in oncology and immunology, making them direct competitors.
Novartis
NVS
Mkt Cap268B
Novartis competes with Telomir Pharmaceuticals in multiple drug categories, including those for chronic diseases, which overlaps with Telomir's product lines.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences competes in the antiviral and oncology sectors, areas where Telomir Pharmaceuticals also aims to innovate.
AMGEN
AMGN
Mkt Cap217.9B
Amgen's focus on biologics and specialty drugs pits it directly against Telomir Pharmaceuticals in the biopharmaceutical market.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie's broad range of pharmaceutical products in immunology and oncology competes with Telomir's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol-Myers Squibb's extensive portfolio in cancer and cardiovascular diseases makes it a significant competitor to Telomir Pharmaceuticals.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly's strong presence in diabetes and cancer treatment areas competes with Telomir Pharmaceuticals' research and drug development.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson's large scale and diverse healthcare products, including pharmaceuticals, make it a formidable competitor across many of Telomir's key areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals, known for its innovative biotechnology products, competes in the same biopharmaceutical niche as Telomir Pharmaceuticals.

About

Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
Show More
CEO
Erez Aminov
Employees
5
Country
United States
ISIN
US87975F1049

Listings

XNAS
US
TELO
BOATS
BOATS
TELO.BOATS

0 Comments

Share your thoughts

FAQs

What is Telomir Pharmaceuticals stock price today?▼
The current price of TELO is $1.05 USD — it has increased by +0% in the past 24 hours. Watch Telomir Pharmaceuticals stock price performance more closely on the chart.
What is Telomir Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Telomir Pharmaceuticals stocks are traded under the ticker TELO.
Is Telomir Pharmaceuticals stock price growing?▼
TELO stock has fallen by -6.25% compared to the previous week, the month change is a -7.08% fall, over the last year Telomir Pharmaceuticals has showed a -35.19% decrease.
What is Telomir Pharmaceuticals market cap?▼
Today Telomir Pharmaceuticals has the market capitalization of 77.3M
When is the next Telomir Pharmaceuticals earnings date?▼
Telomir Pharmaceuticals is going to release the next earnings report on December 2, 2026.
What were Telomir Pharmaceuticals earnings last quarter?▼
TELO earnings for the last quarter are -0.03 USD per share, whereas the estimation was -0.07 USD resulting in a +57.14% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Telomir Pharmaceuticals revenue for the last year?▼
Telomir Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Telomir Pharmaceuticals net income for the last year?▼
TELO net income for the last year is -10.41M USD.
How many employees does Telomir Pharmaceuticals have?▼
As of October 16, 2026, the company has 5 employees.
In which sector is Telomir Pharmaceuticals located?▼
Telomir Pharmaceuticals operates in the Health & Wellness sector.
When did Telomir Pharmaceuticals complete a stock split?▼
Telomir Pharmaceuticals has not had any recent stock splits.
Where is Telomir Pharmaceuticals headquartered?▼
Telomir Pharmaceuticals is headquartered in MIAMI, United States.